SELDI-TOF MS profiling of plasma proteins in ovarian cancer

Shao Pai Wu, Ya Wen Lin, Hung Cheng Lai, Tang Yuan Chu, Yu Liang Kuo, Hang Seng Liu

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: Proteomic profiling of plasma or serum is a technique to identify new biomarkers in disease. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry protein profiling and artificial intelligence. Methods: A total of 65 plasma samples obtained from women with ovarian cancer (n = 35) and age-matched disease-free controls (n = 30) were applied to anion exchange protein chips for protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Results: SELDI-TOF MS was highly reproducible in detecting ovarian tumor-specific protein profiles. One protein peak (relative molecular mass, Mr, 11,537 Da) was identified in plasma from women with ovarian cancer but not in controls. Two peaks, Mr 5,147 and 8,780 Da, were present in the plasma of controls but not of women with ovarian cancer. After a training analysis, classification analysis generated by univariant or linear combination split was performed to reach a discriminant protein signature pattern. After cross validation, a sensitivity of 84% and specificity of 89% for all studied cases and controls was reached. Conclusion: This study clearly demonstrates that the combined technology of SELDI-TOF MS and artificial intelligence is effective in distinguishing protein expression between normal and ovarian cancer plasma. The identified protein peaks may be candidate proteins for early detection of ovarian cancer or evaluation of therapeutic response.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalTaiwanese Journal of Obstetrics and Gynecology
Volume45
Issue number1
Publication statusPublished - Mar 2006
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Blood Proteins
Mass Spectrometry
Lasers
Proteins
Artificial Intelligence
Biomarkers
Antiporters
Protein Array Analysis
Early Detection of Cancer
Proteomics
Membrane Proteins
Technology
Sensitivity and Specificity
Serum
Neoplasms

Keywords

  • Ovarian cancer
  • Protein chip
  • SELDI-TOF mass spectrometry

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Wu, S. P., Lin, Y. W., Lai, H. C., Chu, T. Y., Kuo, Y. L., & Liu, H. S. (2006). SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 45(1), 26-32.

SELDI-TOF MS profiling of plasma proteins in ovarian cancer. / Wu, Shao Pai; Lin, Ya Wen; Lai, Hung Cheng; Chu, Tang Yuan; Kuo, Yu Liang; Liu, Hang Seng.

In: Taiwanese Journal of Obstetrics and Gynecology, Vol. 45, No. 1, 03.2006, p. 26-32.

Research output: Contribution to journalArticle

Wu, SP, Lin, YW, Lai, HC, Chu, TY, Kuo, YL & Liu, HS 2006, 'SELDI-TOF MS profiling of plasma proteins in ovarian cancer', Taiwanese Journal of Obstetrics and Gynecology, vol. 45, no. 1, pp. 26-32.
Wu, Shao Pai ; Lin, Ya Wen ; Lai, Hung Cheng ; Chu, Tang Yuan ; Kuo, Yu Liang ; Liu, Hang Seng. / SELDI-TOF MS profiling of plasma proteins in ovarian cancer. In: Taiwanese Journal of Obstetrics and Gynecology. 2006 ; Vol. 45, No. 1. pp. 26-32.
@article{33dff72a1c3f4852b553336991827793,
title = "SELDI-TOF MS profiling of plasma proteins in ovarian cancer",
abstract = "Objective: Proteomic profiling of plasma or serum is a technique to identify new biomarkers in disease. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry protein profiling and artificial intelligence. Methods: A total of 65 plasma samples obtained from women with ovarian cancer (n = 35) and age-matched disease-free controls (n = 30) were applied to anion exchange protein chips for protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Results: SELDI-TOF MS was highly reproducible in detecting ovarian tumor-specific protein profiles. One protein peak (relative molecular mass, Mr, 11,537 Da) was identified in plasma from women with ovarian cancer but not in controls. Two peaks, Mr 5,147 and 8,780 Da, were present in the plasma of controls but not of women with ovarian cancer. After a training analysis, classification analysis generated by univariant or linear combination split was performed to reach a discriminant protein signature pattern. After cross validation, a sensitivity of 84{\%} and specificity of 89{\%} for all studied cases and controls was reached. Conclusion: This study clearly demonstrates that the combined technology of SELDI-TOF MS and artificial intelligence is effective in distinguishing protein expression between normal and ovarian cancer plasma. The identified protein peaks may be candidate proteins for early detection of ovarian cancer or evaluation of therapeutic response.",
keywords = "Ovarian cancer, Protein chip, SELDI-TOF mass spectrometry",
author = "Wu, {Shao Pai} and Lin, {Ya Wen} and Lai, {Hung Cheng} and Chu, {Tang Yuan} and Kuo, {Yu Liang} and Liu, {Hang Seng}",
year = "2006",
month = "3",
language = "English",
volume = "45",
pages = "26--32",
journal = "Taiwanese Journal of Obstetrics and Gynecology",
issn = "1028-4559",
publisher = "臺灣婦產科醫學會",
number = "1",

}

TY - JOUR

T1 - SELDI-TOF MS profiling of plasma proteins in ovarian cancer

AU - Wu, Shao Pai

AU - Lin, Ya Wen

AU - Lai, Hung Cheng

AU - Chu, Tang Yuan

AU - Kuo, Yu Liang

AU - Liu, Hang Seng

PY - 2006/3

Y1 - 2006/3

N2 - Objective: Proteomic profiling of plasma or serum is a technique to identify new biomarkers in disease. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry protein profiling and artificial intelligence. Methods: A total of 65 plasma samples obtained from women with ovarian cancer (n = 35) and age-matched disease-free controls (n = 30) were applied to anion exchange protein chips for protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Results: SELDI-TOF MS was highly reproducible in detecting ovarian tumor-specific protein profiles. One protein peak (relative molecular mass, Mr, 11,537 Da) was identified in plasma from women with ovarian cancer but not in controls. Two peaks, Mr 5,147 and 8,780 Da, were present in the plasma of controls but not of women with ovarian cancer. After a training analysis, classification analysis generated by univariant or linear combination split was performed to reach a discriminant protein signature pattern. After cross validation, a sensitivity of 84% and specificity of 89% for all studied cases and controls was reached. Conclusion: This study clearly demonstrates that the combined technology of SELDI-TOF MS and artificial intelligence is effective in distinguishing protein expression between normal and ovarian cancer plasma. The identified protein peaks may be candidate proteins for early detection of ovarian cancer or evaluation of therapeutic response.

AB - Objective: Proteomic profiling of plasma or serum is a technique to identify new biomarkers in disease. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry protein profiling and artificial intelligence. Methods: A total of 65 plasma samples obtained from women with ovarian cancer (n = 35) and age-matched disease-free controls (n = 30) were applied to anion exchange protein chips for protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Results: SELDI-TOF MS was highly reproducible in detecting ovarian tumor-specific protein profiles. One protein peak (relative molecular mass, Mr, 11,537 Da) was identified in plasma from women with ovarian cancer but not in controls. Two peaks, Mr 5,147 and 8,780 Da, were present in the plasma of controls but not of women with ovarian cancer. After a training analysis, classification analysis generated by univariant or linear combination split was performed to reach a discriminant protein signature pattern. After cross validation, a sensitivity of 84% and specificity of 89% for all studied cases and controls was reached. Conclusion: This study clearly demonstrates that the combined technology of SELDI-TOF MS and artificial intelligence is effective in distinguishing protein expression between normal and ovarian cancer plasma. The identified protein peaks may be candidate proteins for early detection of ovarian cancer or evaluation of therapeutic response.

KW - Ovarian cancer

KW - Protein chip

KW - SELDI-TOF mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=33645744573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645744573&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 26

EP - 32

JO - Taiwanese Journal of Obstetrics and Gynecology

JF - Taiwanese Journal of Obstetrics and Gynecology

SN - 1028-4559

IS - 1

ER -